Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Christopher J. Halbrook

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3376-3114; OpenAlex author ID A5005221333; NIH RePORTER profile ID 12098579. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 2)
Trials
0
Grants
5
Labs led
1
Collaborators
105
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers, 1 grant · 2020: 1 paper, 1 grant · 2021: 4 papers · 2022: 3 papers, 1 grant · 2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 3 papers, 2 grants

Papers 23

  1. Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Last author DOI 10.1016/j.jcmgh.2026.101872↗
  2. Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2026.09.027↗
  3. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  4. Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. First author DOI 10.1002/ueg2.12773↗
  5. Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer Co-author DOI 10.1101/2025.09.04.673818↗
  6. Pancreatic cancer: Advances and challenges. Co-author DOI 10.1016/j.cell.2023.02.014↗
  7. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  8. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. First author DOI 10.1152/ajpcell.00331.2022↗
  9. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  10. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  11. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  12. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway. Co-author DOI 10.7554/elife.73796↗
  13. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Co-author DOI 10.1038/s41467-021-24859-2↗
  14. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Co-author DOI 10.1101/2021.06.07.447448↗
  15. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  16. Hyaluronic acid fuels pancreatic cancer cell growth. First author DOI 10.7554/elife.62645↗
  17. Clonal Heterogeneity Supports Mitochondrial Metabolism in Pancreatic Cancer Co-author DOI 10.1101/2020.05.15.098368↗
  18. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  19. Metabolism and epigenetics of pancreatic cancer stem cells. Co-author DOI 10.1016/j.semcancer.2018.09.008↗
  20. Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. Co-author DOI 10.1152/ajpgi.00416.2017↗
  21. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.97422↗
  22. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2016.12.006↗
  23. PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Co-author DOI 10.1101/gad.291021.116↗

Grants 5

  1. Harnessing Nutritional Modulation to Enhance Cancer Drug Potency R21CA307778↗
  2. Targeting Metabolic Crosstalk in Pancreatic Cancer R37CA283575↗
  3. Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer R00CA241357↗
  4. Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer K99CA241357↗
  5. Targeting Epithelial-Immune Cell Crosstalk to Improve Therapy in Pancreatic Cancer F32CA228328↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Costas Andreas Lyssiotis · 16 shared papers, 2017–2023 · strength 1.87
  2. Marina Pasca di Magliano · 13 shared papers, 2018–2023 · strength 1.51
  3. Peter Kaiser · 1 shared grant, 2026 · strength 1.26
  4. Rima Singh · 5 shared papers, 2022–2026 · strength 0.84
  5. Alica K. Michels · 4 shared papers, 2025–2026 · strength 0.79
  6. Li Zhang · 7 shared papers, 2019–2023 · strength 0.74
  7. Alica K. Beutel · 3 shared papers, 2022–2025 · strength 0.73
  8. Nina G. Steele · 5 shared papers, 2021–2026 · strength 0.65
  9. Zeribe C. Nwosu · 6 shared papers, 2021–2023 · strength 0.65
  10. Howard C. Crawford · 7 shared papers, 2016–2023 · strength 0.63
  11. Alexander Kleger · 3 shared papers, 2025–2026 · strength 0.62
  12. Thomas Theodor Werner Seufferlein · 3 shared papers, 2025–2026 · strength 0.62
  13. Austin D. Silva · 3 shared papers, 2026 · strength 0.61
  14. Eileen S. Carpenter · 5 shared papers, 2021–2023 · strength 0.55
  15. Yaqing Zhang · 5 shared papers, 2019–2023 · strength 0.53
  16. Alexander Muir · 3 shared papers, 2023–2026 · strength 0.51
  17. Jennifer P. Morton · 4 shared papers, 2018–2026 · strength 0.46
  18. Élodie Roger · 2 shared papers, 2025–2026 · strength 0.42
  19. Johann Gout · 2 shared papers, 2025–2026 · strength 0.42
  20. Lukas Perkhofer · 2 shared papers, 2025–2026 · strength 0.42
  21. Samuel Andrew Kerk · 4 shared papers, 2021–2022 · strength 0.39
  22. Rosa Elena Menjivar · 3 shared papers, 2021–2023 · strength 0.38
  23. Matthew H. Ward · 3 shared papers, 2021–2023 · strength 0.37
  24. Filip Bednar · 3 shared papers, 2019–2023 · strength 0.33
  25. Daniel M. Kremer · 4 shared papers, 2018–2021 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.